Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cellectis S.A. ADR (NQ: CLLS )

1.870 +0.010 (+0.54%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. ADR

< Previous 1 2 3 4 5 6 7 Next >
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
From Cellectis Inc.
Via GlobeNewswire
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
From Cellectis Inc.
Via GlobeNewswire
Recap: Cellectis Q1 Earnings
Via Benzinga
Expert Ratings for Cellectis
Via Benzinga
A Preview Of Cellectis's Earnings
Via Benzinga
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
BALLI-01 (evaluating UCART22) abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL population 
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
From Cellectis Inc.
Via GlobeNewswire
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
From Cellectis Inc.
Via GlobeNewswire
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
From Cellectis Inc.
Via GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
From Cellectis Inc.
Via GlobeNewswire
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
From Cellectis Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Cellectis Announces Pricing of Follow-On Offering
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.